VEGF signal system: the application of antiangiogenesis

Xuewu Liang, Fuming Xu, Xiaoguang Li

  • 1Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong 250012, China. wfxu@yahoo.cn.

Current Medicinal Chemistry
|September 25, 2013
PubMed

Insights

Vascular Endothelial Growth Factor (VEGF) drives angiogenesis and tumor growth. This review details the VEGF signaling system, its role in cancer, and current/novel anti-angiogenic therapies targeting VEGF and its pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis, crucial for tumor growth and metastasis.
  • The VEGF signaling system, including VEGF, its receptors (VEGFR), and downstream pathways, represents a significant target for anticancer therapies.
  • Pathological angiogenesis is implicated in various cancers and other diseases.

Purpose of the Study:

  • To provide a comprehensive review of the VEGF signaling system.
  • To elucidate the molecular mechanisms of VEGF-ligand and receptor interactions.
  • To detail the VEGF downstream signaling pathways and their role in cancer.

Main Methods:

  • Review of existing literature on VEGF signaling and anti-angiogenic agents.
  • Analysis of molecular structures and binding modes of kinase inhibitors.
  • Tabulation of current clinical and approved anticancer agents targeting the VEGF pathway.

Main Results:

  • Detailed interpretation of the VEGF signal system, from molecular structure to receptor binding.
  • Comprehensive overview of VEGF-mediated downstream signaling pathways.
  • Inclusion of up-to-date clinical/approved anticancer agents and their mechanisms, including Structure-Activity Relationships (SAR) of small molecule inhibitors.

Conclusions:

  • The VEGF signaling system is a critical target for anti-cancer drug development.
  • Various anti-angiogenic agents, including antibodies, ribozymes, and small molecule inhibitors, have been developed.
  • Emerging strategies focus on novel targets and inhibitors within the VEGF downstream signaling pathways for enhanced therapeutic efficacy.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...